 Rasika Mathias
Concepts (785)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 89 | 2025 | 1431 | 5.090 |
Why?
| | Polymorphism, Single Nucleotide | 102 | 2025 | 2189 | 4.540 |
Why?
| | Genetic Predisposition to Disease | 68 | 2025 | 2426 | 3.570 |
Why?
| | Peanut Hypersensitivity | 6 | 2023 | 146 | 3.010 |
Why?
| | Asthma | 49 | 2025 | 2295 | 2.860 |
Why?
| | Whole Genome Sequencing | 26 | 2025 | 160 | 2.360 |
Why?
| | Dermatitis, Atopic | 9 | 2023 | 329 | 2.270 |
Why?
| | Precision Medicine | 20 | 2025 | 429 | 2.150 |
Why?
| | Genetic Variation | 30 | 2025 | 991 | 2.020 |
Why?
| | Food Hypersensitivity | 4 | 2023 | 183 | 1.990 |
Why?
| | Fatty Acid Desaturases | 12 | 2021 | 32 | 1.980 |
Why?
| | Immunoglobulin E | 18 | 2021 | 342 | 1.810 |
Why?
| | Genome, Human | 19 | 2025 | 425 | 1.810 |
Why?
| | Arachis | 5 | 2023 | 112 | 1.810 |
Why?
| | Platelet Aggregation | 12 | 2021 | 103 | 1.760 |
Why?
| | Induced Pluripotent Stem Cells | 4 | 2021 | 248 | 1.670 |
Why?
| | Genotype | 42 | 2025 | 1916 | 1.650 |
Why?
| | Exome | 14 | 2022 | 231 | 1.620 |
Why?
| | Genomics | 17 | 2025 | 795 | 1.520 |
Why?
| | Blood Platelets | 12 | 2022 | 408 | 1.470 |
Why?
| | Kaposi Varicelliform Eruption | 4 | 2021 | 21 | 1.410 |
Why?
| | Alleles | 22 | 2023 | 891 | 1.410 |
Why?
| | Genetics, Population | 16 | 2025 | 214 | 1.360 |
Why?
| | Megakaryocytes | 3 | 2021 | 34 | 1.280 |
Why?
| | Phenotype | 51 | 2025 | 3196 | 1.240 |
Why?
| | Genetic Loci | 18 | 2021 | 288 | 1.180 |
Why?
| | Quantitative Trait Loci | 18 | 2025 | 380 | 1.180 |
Why?
| | Fatty Acids, Omega-6 | 5 | 2017 | 48 | 1.170 |
Why?
| | Humans | 241 | 2025 | 137585 | 1.140 |
Why?
| | Multigene Family | 9 | 2021 | 198 | 1.060 |
Why?
| | Coronary Artery Disease | 11 | 2025 | 698 | 1.040 |
Why?
| | DNA Methylation | 7 | 2025 | 643 | 1.000 |
Why?
| | Receptors, Cell Surface | 8 | 2024 | 385 | 1.000 |
Why?
| | Gene Frequency | 23 | 2024 | 521 | 0.960 |
Why?
| | Linoleic Acid | 6 | 2023 | 43 | 0.900 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 12 | 2022 | 104 | 0.890 |
Why?
| | Nasal Mucosa | 2 | 2024 | 107 | 0.880 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2024 | 27 | 0.880 |
Why?
| | Hypersensitivity, Immediate | 2 | 2023 | 44 | 0.840 |
Why?
| | Allergens | 5 | 2023 | 409 | 0.840 |
Why?
| | Immunoglobulin G | 3 | 2022 | 893 | 0.820 |
Why?
| | Transcriptome | 3 | 2022 | 971 | 0.810 |
Why?
| | Genetic Linkage | 14 | 2022 | 297 | 0.810 |
Why?
| | Models, Genetic | 14 | 2025 | 600 | 0.810 |
Why?
| | HLA-DQ alpha-Chains | 2 | 2022 | 16 | 0.780 |
Why?
| | Chromosome Mapping | 16 | 2021 | 523 | 0.760 |
Why?
| | Male | 113 | 2025 | 67762 | 0.740 |
Why?
| | 2S Albumins, Plant | 1 | 2022 | 31 | 0.730 |
Why?
| | Linkage Disequilibrium | 19 | 2022 | 268 | 0.730 |
Why?
| | Mosaicism | 4 | 2025 | 73 | 0.720 |
Why?
| | Antigens, Plant | 1 | 2022 | 54 | 0.720 |
Why?
| | Nucleotide Transport Proteins | 1 | 2021 | 1 | 0.720 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 11 | 2021 | 1040 | 0.720 |
Why?
| | High-Throughput Nucleotide Sequencing | 6 | 2019 | 539 | 0.700 |
Why?
| | Multifactorial Inheritance | 5 | 2025 | 174 | 0.690 |
Why?
| | Female | 113 | 2025 | 73304 | 0.690 |
Why?
| | von Willebrand Factor | 6 | 2025 | 80 | 0.680 |
Why?
| | Antibody Formation | 1 | 2022 | 298 | 0.670 |
Why?
| | Platelet Function Tests | 3 | 2021 | 27 | 0.660 |
Why?
| | Herpesvirus 1, Human | 1 | 2021 | 87 | 0.650 |
Why?
| | Lung | 10 | 2022 | 4060 | 0.650 |
Why?
| | Genetic Association Studies | 13 | 2024 | 377 | 0.640 |
Why?
| | Lipids | 8 | 2023 | 672 | 0.640 |
Why?
| | Middle Aged | 67 | 2025 | 33479 | 0.640 |
Why?
| | Pedigree | 8 | 2025 | 514 | 0.620 |
Why?
| | Open Reading Frames | 3 | 2021 | 123 | 0.590 |
Why?
| | Fibrinogen | 7 | 2024 | 168 | 0.580 |
Why?
| | Adult | 66 | 2025 | 37929 | 0.560 |
Why?
| | Alzheimer Disease | 1 | 2023 | 560 | 0.540 |
Why?
| | Frailty | 3 | 2025 | 170 | 0.530 |
Why?
| | Computational Biology | 5 | 2025 | 644 | 0.520 |
Why?
| | Human Migration | 1 | 2016 | 22 | 0.520 |
Why?
| | Chromosomes, Human, Pair 11 | 5 | 2014 | 59 | 0.520 |
Why?
| | Gene-Environment Interaction | 3 | 2014 | 192 | 0.510 |
Why?
| | Case-Control Studies | 21 | 2025 | 3556 | 0.510 |
Why?
| | Pulmonary Emphysema | 3 | 2014 | 288 | 0.500 |
Why?
| | Platelet Activation | 4 | 2018 | 93 | 0.500 |
Why?
| | Gene Flow | 1 | 2016 | 86 | 0.490 |
Why?
| | Diabetes Mellitus, Type 2 | 10 | 2022 | 2531 | 0.470 |
Why?
| | Software | 5 | 2024 | 665 | 0.470 |
Why?
| | Evolution, Molecular | 3 | 2019 | 493 | 0.460 |
Why?
| | Haplotypes | 14 | 2025 | 494 | 0.460 |
Why?
| | Aging | 5 | 2025 | 1864 | 0.440 |
Why?
| | Geography | 2 | 2016 | 200 | 0.440 |
Why?
| | RNA | 1 | 2021 | 921 | 0.440 |
Why?
| | HLA-B7 Antigen | 1 | 2013 | 7 | 0.430 |
Why?
| | Fatty Acids, Unsaturated | 4 | 2020 | 99 | 0.420 |
Why?
| | Polymorphism, Genetic | 11 | 2017 | 660 | 0.420 |
Why?
| | Risk Factors | 23 | 2025 | 10388 | 0.420 |
Why?
| | Diet | 4 | 2023 | 1278 | 0.420 |
Why?
| | Bronchial Hyperreactivity | 1 | 2014 | 111 | 0.410 |
Why?
| | Epigenesis, Genetic | 6 | 2024 | 660 | 0.410 |
Why?
| | Quantitative Trait, Heritable | 6 | 2021 | 125 | 0.400 |
Why?
| | Interferon-gamma | 3 | 2015 | 789 | 0.400 |
Why?
| | Hypersensitivity | 4 | 2024 | 257 | 0.380 |
Why?
| | Airway Obstruction | 1 | 2014 | 162 | 0.370 |
Why?
| | Child | 30 | 2025 | 21935 | 0.370 |
Why?
| | Immunity, Cellular | 1 | 2013 | 268 | 0.370 |
Why?
| | Fatty Acids, Omega-3 | 3 | 2021 | 140 | 0.360 |
Why?
| | Mutation | 9 | 2024 | 3958 | 0.360 |
Why?
| | Leukocytes | 4 | 2023 | 311 | 0.350 |
Why?
| | Likelihood Functions | 5 | 2012 | 144 | 0.350 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2011 | 65 | 0.350 |
Why?
| | Mendelian Randomization Analysis | 3 | 2024 | 50 | 0.350 |
Why?
| | Dyslipidemias | 3 | 2016 | 176 | 0.350 |
Why?
| | Cardiovascular Diseases | 8 | 2025 | 2111 | 0.350 |
Why?
| | United States | 29 | 2024 | 14841 | 0.340 |
Why?
| | Diabetes Mellitus | 4 | 2023 | 1040 | 0.330 |
Why?
| | Liver | 7 | 2024 | 1943 | 0.330 |
Why?
| | DNA, Mitochondrial | 2 | 2023 | 200 | 0.320 |
Why?
| | Gene Expression Regulation | 9 | 2024 | 2607 | 0.320 |
Why?
| | RNA, Long Noncoding | 2 | 2023 | 181 | 0.320 |
Why?
| | Cell Adhesion Molecules | 2 | 2024 | 181 | 0.320 |
Why?
| | Factor VIII | 2 | 2024 | 98 | 0.320 |
Why?
| | Genome | 4 | 2022 | 300 | 0.320 |
Why?
| | Cohort Studies | 15 | 2021 | 5742 | 0.320 |
Why?
| | Aged | 33 | 2025 | 23961 | 0.320 |
Why?
| | Adolescent | 29 | 2023 | 21513 | 0.320 |
Why?
| | Telomere | 5 | 2024 | 280 | 0.320 |
Why?
| | Biomarkers | 7 | 2024 | 4149 | 0.310 |
Why?
| | Healthcare Disparities | 3 | 2025 | 654 | 0.310 |
Why?
| | Computer Simulation | 8 | 2024 | 978 | 0.300 |
Why?
| | Organ Specificity | 2 | 2021 | 305 | 0.300 |
Why?
| | Chromosome Aberrations | 2 | 2024 | 156 | 0.300 |
Why?
| | Pharmacogenetics | 2 | 2020 | 180 | 0.290 |
Why?
| | Adaptation, Physiological | 1 | 2012 | 553 | 0.290 |
Why?
| | Genetic Pleiotropy | 3 | 2019 | 31 | 0.290 |
Why?
| | Dietary Fats | 1 | 2010 | 304 | 0.290 |
Why?
| | Smoking | 6 | 2018 | 1627 | 0.290 |
Why?
| | HLA-DQ beta-Chains | 2 | 2021 | 63 | 0.280 |
Why?
| | Arachidonic Acid | 6 | 2015 | 120 | 0.280 |
Why?
| | Gene Regulatory Networks | 2 | 2024 | 305 | 0.280 |
Why?
| | Fasting | 2 | 2022 | 281 | 0.270 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 900 | 0.270 |
Why?
| | Body Height | 4 | 2015 | 199 | 0.270 |
Why?
| | Loss of Function Mutation | 3 | 2021 | 46 | 0.260 |
Why?
| | Restless Legs Syndrome | 1 | 2006 | 21 | 0.260 |
Why?
| | Aspirin | 4 | 2018 | 387 | 0.260 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2006 | 19 | 0.260 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2006 | 68 | 0.250 |
Why?
| | Computer Graphics | 1 | 2006 | 42 | 0.250 |
Why?
| | Schistosoma japonicum | 2 | 2017 | 31 | 0.250 |
Why?
| | Biological Specimen Banks | 3 | 2024 | 102 | 0.240 |
Why?
| | Lipoprotein Lipase | 1 | 2006 | 59 | 0.240 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2017 | 767 | 0.240 |
Why?
| | Health Status Disparities | 3 | 2025 | 289 | 0.240 |
Why?
| | Serine | 1 | 2006 | 141 | 0.240 |
Why?
| | Blood Proteins | 2 | 2024 | 252 | 0.240 |
Why?
| | Hematopoietic Stem Cells | 3 | 2024 | 406 | 0.240 |
Why?
| | Helminthiasis | 2 | 2017 | 12 | 0.240 |
Why?
| | Endophenotypes | 1 | 2025 | 21 | 0.240 |
Why?
| | von Willebrand Diseases | 1 | 2025 | 27 | 0.230 |
Why?
| | Genomic Structural Variation | 1 | 2025 | 12 | 0.230 |
Why?
| | Hematopoiesis | 2 | 2023 | 192 | 0.230 |
Why?
| | Chromosomes, Human, Y | 1 | 2025 | 24 | 0.230 |
Why?
| | Models, Statistical | 7 | 2021 | 669 | 0.230 |
Why?
| | Membrane Proteins | 7 | 2017 | 1164 | 0.230 |
Why?
| | Germ-Line Mutation | 2 | 2023 | 172 | 0.230 |
Why?
| | Cholesterol, HDL | 4 | 2016 | 203 | 0.230 |
Why?
| | Consanguinity | 2 | 2005 | 49 | 0.230 |
Why?
| | Inflammation | 6 | 2024 | 2837 | 0.230 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2025 | 43 | 0.230 |
Why?
| | Chromosome Deletion | 1 | 2025 | 115 | 0.220 |
Why?
| | Kininogens | 1 | 2024 | 6 | 0.220 |
Why?
| | Young Adult | 13 | 2022 | 13209 | 0.220 |
Why?
| | Chromosomes, Human, Pair 16 | 3 | 2021 | 36 | 0.220 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2691 | 0.220 |
Why?
| | Lectins, C-Type | 1 | 2024 | 67 | 0.220 |
Why?
| | Telomere Homeostasis | 1 | 2024 | 34 | 0.220 |
Why?
| | Interleukin-13 | 3 | 2023 | 149 | 0.220 |
Why?
| | Chemokines, CC | 2 | 2014 | 33 | 0.220 |
Why?
| | Forced Expiratory Volume | 4 | 2019 | 531 | 0.210 |
Why?
| | Liver Cirrhosis | 2 | 2017 | 316 | 0.210 |
Why?
| | Blood Pressure | 6 | 2022 | 1786 | 0.210 |
Why?
| | Fibronectins | 1 | 2024 | 133 | 0.210 |
Why?
| | Population Groups | 3 | 2019 | 62 | 0.210 |
Why?
| | Menopause, Premature | 1 | 2023 | 12 | 0.210 |
Why?
| | Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 2 | 2022 | 2 | 0.210 |
Why?
| | Barbados | 8 | 2013 | 8 | 0.210 |
Why?
| | Erythrocytes | 2 | 2021 | 700 | 0.200 |
Why?
| | Respiration | 2 | 2014 | 199 | 0.200 |
Why?
| | Proteomics | 3 | 2024 | 1111 | 0.200 |
Why?
| | Blood Cells | 1 | 2022 | 40 | 0.200 |
Why?
| | Frameshift Mutation | 1 | 2022 | 32 | 0.200 |
Why?
| | Metabolic Syndrome | 3 | 2011 | 354 | 0.200 |
Why?
| | Interleukin-4 | 2 | 2023 | 216 | 0.200 |
Why?
| | Chromosomes, Human, X | 2 | 2021 | 73 | 0.190 |
Why?
| | Promoter Regions, Genetic | 6 | 2023 | 1250 | 0.190 |
Why?
| | Telomere Shortening | 1 | 2022 | 20 | 0.190 |
Why?
| | Eczema | 1 | 2023 | 69 | 0.190 |
Why?
| | Proteome | 2 | 2024 | 472 | 0.190 |
Why?
| | Acute Coronary Syndrome | 2 | 2016 | 279 | 0.190 |
Why?
| | Genetic Heterogeneity | 3 | 2016 | 59 | 0.190 |
Why?
| | Desensitization, Immunologic | 1 | 2023 | 96 | 0.190 |
Why?
| | Gastritis | 1 | 2023 | 108 | 0.190 |
Why?
| | Nerve Tissue Proteins | 5 | 2022 | 596 | 0.190 |
Why?
| | Coronary Disease | 2 | 2019 | 385 | 0.180 |
Why?
| | Enteritis | 1 | 2023 | 103 | 0.180 |
Why?
| | Pseudomonas Infections | 2 | 2015 | 225 | 0.180 |
Why?
| | HLA-A2 Antigen | 1 | 2021 | 48 | 0.180 |
Why?
| | Dinoprostone | 1 | 2022 | 191 | 0.180 |
Why?
| | Americas | 1 | 2021 | 28 | 0.180 |
Why?
| | Spain | 1 | 2021 | 41 | 0.180 |
Why?
| | Cyclooxygenase Inhibitors | 2 | 2014 | 79 | 0.180 |
Why?
| | DNA Copy Number Variations | 2 | 2020 | 182 | 0.180 |
Why?
| | Peru | 1 | 2021 | 58 | 0.180 |
Why?
| | Leishmaniasis, Visceral | 1 | 2001 | 22 | 0.180 |
Why?
| | Gene Ontology | 1 | 2021 | 53 | 0.180 |
Why?
| | Pulmonary Medicine | 2 | 2019 | 85 | 0.180 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2021 | 86 | 0.170 |
Why?
| | Glutathione Transferase | 1 | 2021 | 106 | 0.170 |
Why?
| | Odds Ratio | 7 | 2019 | 1070 | 0.170 |
Why?
| | Cytokines | 4 | 2023 | 2085 | 0.170 |
Why?
| | Social Determinants of Health | 1 | 2025 | 267 | 0.170 |
Why?
| | Risk | 7 | 2019 | 912 | 0.170 |
Why?
| | gamma-Linolenic Acid | 1 | 2020 | 2 | 0.170 |
Why?
| | Algorithms | 7 | 2025 | 1704 | 0.170 |
Why?
| | Immunologic Factors | 1 | 2022 | 236 | 0.170 |
Why?
| | Chromosomes, Human, Pair 19 | 3 | 2012 | 25 | 0.170 |
Why?
| | Lipid Metabolism | 2 | 2021 | 518 | 0.170 |
Why?
| | Receptors, Nicotinic | 2 | 2013 | 334 | 0.170 |
Why?
| | Hemorrhage | 1 | 2025 | 722 | 0.170 |
Why?
| | HLA-DQ Antigens | 1 | 2021 | 181 | 0.170 |
Why?
| | Soybean Oil | 1 | 2020 | 14 | 0.170 |
Why?
| | Plant Oils | 1 | 2020 | 31 | 0.170 |
Why?
| | Energy Intake | 1 | 2023 | 485 | 0.170 |
Why?
| | Amish | 1 | 2020 | 7 | 0.170 |
Why?
| | beta-Globins | 1 | 2019 | 8 | 0.160 |
Why?
| | Platelet Aggregation Inhibitors | 2 | 2018 | 463 | 0.160 |
Why?
| | Base Sequence | 4 | 2021 | 2181 | 0.160 |
Why?
| | Thrombosis | 5 | 2024 | 371 | 0.160 |
Why?
| | Genomic Instability | 1 | 2020 | 53 | 0.160 |
Why?
| | Occipital Lobe | 1 | 2019 | 22 | 0.160 |
Why?
| | Cholesterol, LDL | 5 | 2022 | 365 | 0.160 |
Why?
| | Tissue Plasminogen Activator | 1 | 2021 | 224 | 0.160 |
Why?
| | Homozygote | 3 | 2016 | 203 | 0.160 |
Why?
| | HLA-DRB1 Chains | 1 | 2020 | 112 | 0.160 |
Why?
| | 8,11,14-Eicosatrienoic Acid | 3 | 2020 | 6 | 0.160 |
Why?
| | Diabetic Nephropathies | 1 | 2023 | 294 | 0.160 |
Why?
| | Mutation, Missense | 2 | 2023 | 341 | 0.160 |
Why?
| | Aged, 80 and over | 10 | 2025 | 7635 | 0.160 |
Why?
| | Eicosanoids | 2 | 2022 | 62 | 0.150 |
Why?
| | Chromosomes, Human, Pair 12 | 4 | 2019 | 21 | 0.150 |
Why?
| | Photometry | 1 | 2019 | 4 | 0.150 |
Why?
| | Parietal Lobe | 1 | 2019 | 58 | 0.150 |
Why?
| | Brain | 2 | 2023 | 2668 | 0.150 |
Why?
| | Th2 Cells | 4 | 2023 | 176 | 0.150 |
Why?
| | Genes, Mitochondrial | 1 | 2018 | 14 | 0.150 |
Why?
| | Chromatography, Gas | 1 | 2019 | 33 | 0.150 |
Why?
| | Plasticizers | 1 | 2019 | 15 | 0.150 |
Why?
| | Flame Retardants | 1 | 2019 | 11 | 0.150 |
Why?
| | Sleep Medicine Specialty | 1 | 2019 | 11 | 0.150 |
Why?
| | Brazil | 6 | 2017 | 167 | 0.150 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2025 | 52 | 0.150 |
Why?
| | Clinical Trials as Topic | 2 | 2022 | 1050 | 0.150 |
Why?
| | Temporal Lobe | 1 | 2019 | 91 | 0.150 |
Why?
| | Metabolomics | 2 | 2024 | 678 | 0.150 |
Why?
| | India | 3 | 2009 | 195 | 0.150 |
Why?
| | Receptors, Immunologic | 3 | 2022 | 216 | 0.150 |
Why?
| | Metabolism | 1 | 2018 | 42 | 0.150 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 2018 | 10 | 0.150 |
Why?
| | Sex Characteristics | 3 | 2014 | 762 | 0.150 |
Why?
| | Databases, Genetic | 4 | 2021 | 237 | 0.150 |
Why?
| | Smad2 Protein | 1 | 2018 | 38 | 0.150 |
Why?
| | Family | 4 | 2012 | 671 | 0.150 |
Why?
| | Eosinophilic Esophagitis | 1 | 2023 | 325 | 0.150 |
Why?
| | Hominidae | 1 | 2019 | 85 | 0.150 |
Why?
| | Computer Communication Networks | 1 | 2018 | 33 | 0.150 |
Why?
| | Frontal Lobe | 1 | 2019 | 149 | 0.140 |
Why?
| | Blood Glucose | 4 | 2021 | 2186 | 0.140 |
Why?
| | Child, Preschool | 16 | 2021 | 11074 | 0.140 |
Why?
| | Exons | 3 | 2016 | 355 | 0.140 |
Why?
| | Indians, North American | 2 | 2021 | 643 | 0.140 |
Why?
| | Lipopolysaccharide Receptors | 2 | 2010 | 85 | 0.140 |
Why?
| | Organophosphates | 1 | 2019 | 134 | 0.140 |
Why?
| | Telomerase | 2 | 2024 | 250 | 0.140 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2017 | 35 | 0.140 |
Why?
| | Immunotherapy | 1 | 2022 | 641 | 0.140 |
Why?
| | DNA-Binding Proteins | 3 | 2020 | 1502 | 0.140 |
Why?
| | Comorbidity | 1 | 2023 | 1622 | 0.140 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 411 | 0.140 |
Why?
| | Africa | 2 | 2020 | 108 | 0.140 |
Why?
| | Noncommunicable Diseases | 1 | 2017 | 18 | 0.140 |
Why?
| | Quality Control | 4 | 2021 | 172 | 0.140 |
Why?
| | Hyaluronoglucosaminidase | 1 | 2017 | 8 | 0.140 |
Why?
| | Information Storage and Retrieval | 1 | 2018 | 118 | 0.140 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2017 | 91 | 0.140 |
Why?
| | Molecular Epidemiology | 3 | 2013 | 68 | 0.130 |
Why?
| | Rural Health | 1 | 1997 | 80 | 0.130 |
Why?
| | Schistosoma mansoni | 1 | 2017 | 37 | 0.130 |
Why?
| | Endemic Diseases | 1 | 2017 | 32 | 0.130 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 746 | 0.130 |
Why?
| | Animals | 19 | 2023 | 36940 | 0.130 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2017 | 26 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2020 | 512 | 0.130 |
Why?
| | Scavenger Receptors, Class B | 1 | 2016 | 14 | 0.130 |
Why?
| | Sequence Analysis, DNA | 6 | 2018 | 812 | 0.130 |
Why?
| | Cyclooxygenase 1 | 2 | 2014 | 27 | 0.130 |
Why?
| | DNA, Intergenic | 1 | 2016 | 26 | 0.130 |
Why?
| | Schistosomiasis | 1 | 2017 | 47 | 0.130 |
Why?
| | Carotid Artery Diseases | 1 | 2016 | 64 | 0.130 |
Why?
| | Decision Support Systems, Clinical | 1 | 2020 | 226 | 0.130 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 617 | 0.130 |
Why?
| | Enhancer Elements, Genetic | 1 | 2017 | 190 | 0.130 |
Why?
| | White Matter | 1 | 2018 | 145 | 0.130 |
Why?
| | Erythropoiesis | 1 | 2016 | 55 | 0.130 |
Why?
| | Myocardial Infarction | 2 | 2020 | 1046 | 0.120 |
Why?
| | Immune System Diseases | 1 | 2016 | 39 | 0.120 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2017 | 165 | 0.120 |
Why?
| | Mitochondrial Proteins | 1 | 2018 | 257 | 0.120 |
Why?
| | Sexism | 1 | 2016 | 61 | 0.120 |
Why?
| | Lipoprotein(a) | 1 | 2016 | 67 | 0.120 |
Why?
| | Lung Diseases, Interstitial | 1 | 2022 | 638 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 565 | 0.120 |
Why?
| | Anthropometry | 2 | 2022 | 213 | 0.120 |
Why?
| | Cell Differentiation | 2 | 2021 | 1991 | 0.120 |
Why?
| | Leukocytes, Mononuclear | 2 | 2021 | 558 | 0.120 |
Why?
| | Kidney Transplantation | 2 | 2012 | 708 | 0.120 |
Why?
| | Genes, Modifier | 1 | 2015 | 2 | 0.120 |
Why?
| | Caveolin 2 | 1 | 2015 | 2 | 0.120 |
Why?
| | CpG Islands | 3 | 2023 | 157 | 0.120 |
Why?
| | Factor VII | 1 | 2015 | 24 | 0.120 |
Why?
| | Molecular Sequence Annotation | 3 | 2021 | 99 | 0.120 |
Why?
| | United Kingdom | 3 | 2021 | 318 | 0.120 |
Why?
| | Receptors, Interferon | 1 | 2015 | 52 | 0.120 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 184 | 0.120 |
Why?
| | Collagen | 2 | 2015 | 452 | 0.120 |
Why?
| | Machine Learning | 3 | 2025 | 493 | 0.120 |
Why?
| | Schistosomiasis japonica | 1 | 2015 | 32 | 0.120 |
Why?
| | Mutation Rate | 1 | 2015 | 30 | 0.120 |
Why?
| | Minority Groups | 1 | 2017 | 266 | 0.120 |
Why?
| | Interleukin-10 | 2 | 2017 | 302 | 0.110 |
Why?
| | Adenosine Triphosphatases | 1 | 2016 | 168 | 0.110 |
Why?
| | Scleroderma, Systemic | 1 | 2016 | 122 | 0.110 |
Why?
| | Menopause | 2 | 2023 | 320 | 0.110 |
Why?
| | Cross-Sectional Studies | 6 | 2024 | 5472 | 0.110 |
Why?
| | Mutant Chimeric Proteins | 1 | 2014 | 5 | 0.110 |
Why?
| | KCNQ1 Potassium Channel | 1 | 2014 | 7 | 0.110 |
Why?
| | HMGA2 Protein | 1 | 2014 | 9 | 0.110 |
Why?
| | Severity of Illness Index | 4 | 2019 | 2828 | 0.110 |
Why?
| | HLA-B27 Antigen | 1 | 2014 | 16 | 0.110 |
Why?
| | Chromosome Disorders | 1 | 2014 | 43 | 0.110 |
Why?
| | Transcription Factor 7-Like 2 Protein | 1 | 2014 | 26 | 0.110 |
Why?
| | Hypertension | 2 | 2022 | 1295 | 0.110 |
Why?
| | Rhinitis, Allergic | 1 | 2014 | 40 | 0.110 |
Why?
| | Family Health | 4 | 2011 | 196 | 0.110 |
Why?
| | Cystic Fibrosis | 2 | 2015 | 1114 | 0.110 |
Why?
| | Transmembrane Activator and CAML Interactor Protein | 1 | 2013 | 4 | 0.110 |
Why?
| | beta-Defensins | 1 | 2013 | 21 | 0.110 |
Why?
| | Body Mass Index | 5 | 2022 | 2389 | 0.110 |
Why?
| | Obesity | 2 | 2022 | 2992 | 0.100 |
Why?
| | Critical Care | 1 | 2019 | 601 | 0.100 |
Why?
| | Stroke | 1 | 2022 | 1120 | 0.100 |
Why?
| | Tobacco Use Disorder | 2 | 2013 | 251 | 0.100 |
Why?
| | Pseudomonas aeruginosa | 2 | 2015 | 352 | 0.100 |
Why?
| | Vital Capacity | 1 | 2014 | 311 | 0.100 |
Why?
| | Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 1993 | 14 | 0.100 |
Why?
| | Longitudinal Studies | 5 | 2021 | 2844 | 0.100 |
Why?
| | Kv Channel-Interacting Proteins | 1 | 2013 | 3 | 0.100 |
Why?
| | Chemokine CXCL12 | 1 | 2013 | 81 | 0.100 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2011 | 71 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2017 | 561 | 0.100 |
Why?
| | Professional Impairment | 1 | 1993 | 3 | 0.100 |
Why?
| | Cells, Cultured | 1 | 2021 | 4193 | 0.100 |
Why?
| | Virginia | 2 | 2005 | 62 | 0.100 |
Why?
| | Dentists | 1 | 1993 | 20 | 0.100 |
Why?
| | Family Practice | 1 | 1997 | 464 | 0.100 |
Why?
| | HEK293 Cells | 3 | 2021 | 730 | 0.100 |
Why?
| | Parents | 3 | 2007 | 1347 | 0.100 |
Why?
| | Genetic Markers | 5 | 2016 | 344 | 0.100 |
Why?
| | K562 Cells | 2 | 2024 | 89 | 0.100 |
Why?
| | Skin Tests | 4 | 2017 | 101 | 0.100 |
Why?
| | Principal Component Analysis | 2 | 2010 | 195 | 0.100 |
Why?
| | Hepatocyte Nuclear Factor 3-alpha | 1 | 2012 | 8 | 0.100 |
Why?
| | Ankyrins | 1 | 2012 | 13 | 0.100 |
Why?
| | Kallikreins | 1 | 2012 | 29 | 0.100 |
Why?
| | Duffy Blood-Group System | 2 | 2011 | 6 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 1997 | 486 | 0.100 |
Why?
| | Nuclear Proteins | 1 | 2017 | 712 | 0.100 |
Why?
| | Fatty Acids | 1 | 2015 | 443 | 0.100 |
Why?
| | Phylogeny | 1 | 2016 | 904 | 0.100 |
Why?
| | Microbiota | 1 | 2020 | 762 | 0.100 |
Why?
| | Triglycerides | 3 | 2015 | 524 | 0.100 |
Why?
| | Hepatitis B | 1 | 1993 | 70 | 0.090 |
Why?
| | Atherosclerosis | 1 | 2016 | 415 | 0.090 |
Why?
| | Mitochondria | 1 | 2018 | 948 | 0.090 |
Why?
| | Leukocyte Count | 2 | 2011 | 329 | 0.090 |
Why?
| | Respiratory Sounds | 1 | 2012 | 125 | 0.090 |
Why?
| | Prostate-Specific Antigen | 1 | 2012 | 162 | 0.090 |
Why?
| | Insulin | 4 | 2022 | 2409 | 0.090 |
Why?
| | Steroids | 1 | 2012 | 167 | 0.090 |
Why?
| | Heterozygote | 3 | 2021 | 293 | 0.090 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2011 | 16 | 0.090 |
Why?
| | Patients | 1 | 1993 | 175 | 0.090 |
Why?
| | Infant | 9 | 2021 | 9465 | 0.090 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2011 | 41 | 0.090 |
Why?
| | Aquaporin 5 | 1 | 2010 | 3 | 0.090 |
Why?
| | Reproducibility of Results | 6 | 2021 | 3284 | 0.090 |
Why?
| | Microtubule-Associated Proteins | 1 | 2012 | 196 | 0.090 |
Why?
| | Disease Progression | 5 | 2019 | 2757 | 0.090 |
Why?
| | Heredity | 2 | 2021 | 13 | 0.090 |
Why?
| | Chromosomes | 1 | 2011 | 107 | 0.090 |
Why?
| | Cockroaches | 1 | 2010 | 22 | 0.080 |
Why?
| | Curriculum | 1 | 1997 | 992 | 0.080 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2010 | 30 | 0.080 |
Why?
| | Death Domain Receptor Signaling Adaptor Proteins | 1 | 2009 | 2 | 0.080 |
Why?
| | Recombination, Genetic | 1 | 2011 | 204 | 0.080 |
Why?
| | Interviews as Topic | 2 | 2006 | 786 | 0.080 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 1 | 2010 | 37 | 0.080 |
Why?
| | Mice | 10 | 2023 | 17787 | 0.080 |
Why?
| | Eosinophils | 2 | 2025 | 332 | 0.080 |
Why?
| | Myocardial Ischemia | 1 | 2011 | 263 | 0.080 |
Why?
| | Incidence | 4 | 2019 | 2804 | 0.080 |
Why?
| | Lectins | 1 | 2010 | 49 | 0.080 |
Why?
| | Receptors, Kainic Acid | 1 | 2009 | 10 | 0.080 |
Why?
| | Nuclear Family | 2 | 2007 | 54 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3566 | 0.080 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2009 | 66 | 0.080 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2009 | 10 | 0.080 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2009 | 77 | 0.080 |
Why?
| | Isoenzymes | 1 | 2010 | 304 | 0.080 |
Why?
| | Chromosomes, Human | 1 | 2009 | 44 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2017 | 986 | 0.080 |
Why?
| | Renal Dialysis | 1 | 1993 | 435 | 0.080 |
Why?
| | Caribbean Region | 4 | 2011 | 28 | 0.080 |
Why?
| | Tryptophan | 1 | 2010 | 183 | 0.080 |
Why?
| | Receptors, Leptin | 1 | 2009 | 23 | 0.080 |
Why?
| | Confidence Intervals | 2 | 2014 | 329 | 0.080 |
Why?
| | Interferon-alpha | 1 | 2010 | 198 | 0.080 |
Why?
| | Arginine | 1 | 2010 | 271 | 0.080 |
Why?
| | Agammaglobulinemia | 1 | 1989 | 34 | 0.080 |
Why?
| | Nephrotic Syndrome | 1 | 1989 | 39 | 0.080 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2009 | 59 | 0.070 |
Why?
| | Regression Analysis | 3 | 2025 | 1024 | 0.070 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2022 | 382 | 0.070 |
Why?
| | Graft Rejection | 1 | 2012 | 624 | 0.070 |
Why?
| | Genotyping Techniques | 2 | 2019 | 75 | 0.070 |
Why?
| | Thromboxane B2 | 3 | 2018 | 26 | 0.070 |
Why?
| | Proteoglycans | 1 | 2009 | 107 | 0.070 |
Why?
| | Cholesterol | 2 | 2015 | 410 | 0.070 |
Why?
| | Alcoholism | 3 | 2005 | 807 | 0.070 |
Why?
| | Siblings | 2 | 2011 | 228 | 0.070 |
Why?
| | Chromosomes, Human, Pair 17 | 3 | 2019 | 55 | 0.070 |
Why?
| | Polymerase Chain Reaction | 2 | 2012 | 1062 | 0.070 |
Why?
| | Myosin-Light-Chain Kinase | 1 | 2007 | 20 | 0.070 |
Why?
| | Cognition | 1 | 2015 | 1153 | 0.070 |
Why?
| | Research Design | 2 | 2019 | 1139 | 0.070 |
Why?
| | British Columbia | 3 | 1997 | 21 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 890 | 0.070 |
Why?
| | Age of Onset | 3 | 2013 | 518 | 0.070 |
Why?
| | Antigens, CD | 1 | 2010 | 521 | 0.070 |
Why?
| | Databases, Factual | 1 | 2012 | 1357 | 0.070 |
Why?
| | Inheritance Patterns | 1 | 2006 | 45 | 0.060 |
Why?
| | Thrombophilia | 1 | 2007 | 83 | 0.060 |
Why?
| | Infant, Newborn | 6 | 2012 | 6079 | 0.060 |
Why?
| | Registries | 1 | 2014 | 2035 | 0.060 |
Why?
| | Deoxyribonuclease HindIII | 1 | 2006 | 3 | 0.060 |
Why?
| | alpha-Linolenic Acid | 2 | 2017 | 8 | 0.060 |
Why?
| | Europe | 2 | 2020 | 414 | 0.060 |
Why?
| | Adenosine Diphosphate | 2 | 2017 | 79 | 0.060 |
Why?
| | Meta-Analysis as Topic | 3 | 2012 | 186 | 0.060 |
Why?
| | Neoplasm Proteins | 2 | 2022 | 434 | 0.060 |
Why?
| | Chromosomes, Human, Pair 4 | 2 | 2019 | 30 | 0.060 |
Why?
| | Platelet Count | 2 | 2016 | 86 | 0.060 |
Why?
| | Prospective Studies | 5 | 2020 | 7604 | 0.060 |
Why?
| | Epinephrine | 2 | 2017 | 139 | 0.060 |
Why?
| | DNA Mutational Analysis | 2 | 2020 | 399 | 0.060 |
Why?
| | Glucose | 2 | 2022 | 1020 | 0.060 |
Why?
| | Transfection | 3 | 2016 | 945 | 0.060 |
Why?
| | ABO Blood-Group System | 1 | 2025 | 51 | 0.060 |
Why?
| | Mucins | 1 | 2005 | 73 | 0.060 |
Why?
| | Receptors, Prostaglandin | 1 | 2004 | 22 | 0.060 |
Why?
| | Complement C3 | 1 | 2006 | 209 | 0.060 |
Why?
| | Immunoglobulins | 1 | 2005 | 171 | 0.060 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2024 | 26 | 0.060 |
Why?
| | Mites | 1 | 2004 | 7 | 0.060 |
Why?
| | Janus Kinase 2 | 1 | 2024 | 32 | 0.060 |
Why?
| | National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2024 | 21 | 0.050 |
Why?
| | Loss of Heterozygosity | 1 | 2024 | 51 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2016 | 1910 | 0.050 |
Why?
| | Gene Targeting | 2 | 2020 | 81 | 0.050 |
Why?
| | Kidney | 2 | 2023 | 1468 | 0.050 |
Why?
| | Eye Proteins | 2 | 2021 | 92 | 0.050 |
Why?
| | Matched-Pair Analysis | 1 | 2003 | 39 | 0.050 |
Why?
| | Chromosomes, Human, Pair 14 | 2 | 2014 | 21 | 0.050 |
Why?
| | Adult Children | 1 | 2003 | 24 | 0.050 |
Why?
| | Time | 1 | 2003 | 83 | 0.050 |
Why?
| | Receptors, Complement | 1 | 2004 | 122 | 0.050 |
Why?
| | Diabetic Retinopathy | 1 | 2006 | 189 | 0.050 |
Why?
| | Societies, Medical | 2 | 2019 | 820 | 0.050 |
Why?
| | Epigenomics | 1 | 2024 | 115 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2014 | 4295 | 0.050 |
Why?
| | Guanine Nucleotide Dissociation Inhibitors | 1 | 2023 | 2 | 0.050 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2024 | 107 | 0.050 |
Why?
| | Genes | 1 | 2003 | 230 | 0.050 |
Why?
| | Sex Factors | 3 | 2014 | 2071 | 0.050 |
Why?
| | Aminopeptidases | 1 | 2023 | 18 | 0.050 |
Why?
| | Eosinophilia | 2 | 2023 | 218 | 0.050 |
Why?
| | Point Mutation | 1 | 2004 | 235 | 0.050 |
Why?
| | Electroencephalography | 1 | 2005 | 423 | 0.050 |
Why?
| | Gene Expression Profiling | 1 | 2010 | 1774 | 0.050 |
Why?
| | Environment | 2 | 2010 | 358 | 0.050 |
Why?
| | Membrane Glycoproteins | 2 | 2005 | 500 | 0.050 |
Why?
| | CRISPR-Cas Systems | 1 | 2024 | 125 | 0.050 |
Why?
| | Genes, Reporter | 2 | 2015 | 269 | 0.050 |
Why?
| | Cooperative Behavior | 1 | 2005 | 451 | 0.050 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2022 | 16 | 0.050 |
Why?
| | Cell Line | 3 | 2015 | 2847 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2016 | 2833 | 0.050 |
Why?
| | Pruritus | 1 | 2023 | 63 | 0.050 |
Why?
| | Syndrome | 1 | 2023 | 358 | 0.050 |
Why?
| | Frail Elderly | 1 | 2023 | 131 | 0.050 |
Why?
| | Fruit | 1 | 2023 | 140 | 0.050 |
Why?
| | Vegetables | 1 | 2023 | 157 | 0.050 |
Why?
| | Risk Assessment | 2 | 2025 | 3457 | 0.050 |
Why?
| | Colorado | 2 | 2024 | 4565 | 0.050 |
Why?
| | Gene Expression | 3 | 2015 | 1502 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2023 | 266 | 0.050 |
Why?
| | Age Factors | 3 | 2003 | 3295 | 0.050 |
Why?
| | RGS Proteins | 1 | 2021 | 18 | 0.050 |
Why?
| | Internationality | 2 | 2013 | 155 | 0.050 |
Why?
| | Antigens, Protozoan | 1 | 2001 | 24 | 0.040 |
Why?
| | Subcutaneous Tissue | 1 | 2021 | 24 | 0.040 |
Why?
| | Postmenopause | 1 | 2023 | 366 | 0.040 |
Why?
| | INDEL Mutation | 1 | 2021 | 16 | 0.040 |
Why?
| | Colombia | 2 | 2013 | 41 | 0.040 |
Why?
| | Antibodies, Protozoan | 1 | 2001 | 36 | 0.040 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2021 | 30 | 0.040 |
Why?
| | alpha Karyopherins | 1 | 2020 | 11 | 0.040 |
Why?
| | Receptors, LDL | 1 | 2020 | 47 | 0.040 |
Why?
| | Antibodies, Heterophile | 1 | 2000 | 14 | 0.040 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2021 | 82 | 0.040 |
Why?
| | Cricetinae | 1 | 2001 | 289 | 0.040 |
Why?
| | Lymphocytosis | 1 | 2000 | 11 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2021 | 121 | 0.040 |
Why?
| | Sepsis | 1 | 2007 | 617 | 0.040 |
Why?
| | GTP-Binding Proteins | 1 | 2021 | 161 | 0.040 |
Why?
| | Tripartite Motif Proteins | 1 | 2020 | 41 | 0.040 |
Why?
| | Prognosis | 2 | 2021 | 4030 | 0.040 |
Why?
| | Population Density | 1 | 2021 | 95 | 0.040 |
Why?
| | Sample Size | 1 | 2021 | 125 | 0.040 |
Why?
| | Lod Score | 3 | 2009 | 67 | 0.040 |
Why?
| | Dioxygenases | 1 | 2020 | 26 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2021 | 82 | 0.040 |
Why?
| | Cell Self Renewal | 1 | 2020 | 56 | 0.040 |
Why?
| | Eating | 1 | 2023 | 380 | 0.040 |
Why?
| | Names | 1 | 2000 | 15 | 0.040 |
Why?
| | Gene Editing | 1 | 2021 | 80 | 0.040 |
Why?
| | Lens, Crystalline | 1 | 2001 | 125 | 0.040 |
Why?
| | Mutagenesis | 1 | 2021 | 179 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2006 | 828 | 0.040 |
Why?
| | Respiratory Function Tests | 2 | 2013 | 600 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C19 | 1 | 2020 | 25 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2024 | 778 | 0.040 |
Why?
| | Mucin-5B | 1 | 2022 | 224 | 0.040 |
Why?
| | Emigration and Immigration | 1 | 2000 | 46 | 0.040 |
Why?
| | Gene Silencing | 1 | 2020 | 195 | 0.040 |
Why?
| | A549 Cells | 1 | 2019 | 66 | 0.040 |
Why?
| | Fibrinolysis | 1 | 2021 | 146 | 0.040 |
Why?
| | North America | 2 | 2011 | 313 | 0.040 |
Why?
| | Siberia | 1 | 2019 | 9 | 0.040 |
Why?
| | Body Weight | 1 | 2003 | 985 | 0.040 |
Why?
| | Information Dissemination | 1 | 2021 | 218 | 0.040 |
Why?
| | Recombinases | 1 | 2019 | 6 | 0.040 |
Why?
| | Flame Ionization | 1 | 2019 | 2 | 0.040 |
Why?
| | Event-Related Potentials, P300 | 1 | 1999 | 14 | 0.040 |
Why?
| | Cloud Computing | 1 | 2019 | 7 | 0.040 |
Why?
| | Chromosomes, Human, Pair 8 | 1 | 2019 | 36 | 0.040 |
Why?
| | Waist-Hip Ratio | 1 | 2018 | 39 | 0.040 |
Why?
| | Linear Models | 2 | 2017 | 849 | 0.040 |
Why?
| | Monoamine Oxidase | 1 | 1999 | 30 | 0.040 |
Why?
| | Cataract | 1 | 2001 | 213 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2014 | 1266 | 0.040 |
Why?
| | Antibodies, Viral | 2 | 2000 | 625 | 0.040 |
Why?
| | Limit of Detection | 1 | 2019 | 85 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2022 | 617 | 0.040 |
Why?
| | Prevalence | 2 | 2016 | 2734 | 0.040 |
Why?
| | RNA Splicing Factors | 1 | 2019 | 53 | 0.040 |
Why?
| | Endothelial Cells | 1 | 2024 | 785 | 0.040 |
Why?
| | Calibration | 1 | 2019 | 146 | 0.040 |
Why?
| | Organ Size | 1 | 2019 | 477 | 0.040 |
Why?
| | Reference Standards | 1 | 2019 | 186 | 0.040 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2018 | 10 | 0.040 |
Why?
| | Disease Susceptibility | 2 | 2014 | 347 | 0.040 |
Why?
| | Virus Diseases | 1 | 2000 | 212 | 0.040 |
Why?
| | Skin | 1 | 2023 | 752 | 0.040 |
Why?
| | HIV Infections | 1 | 1993 | 2836 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2019 | 688 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2020 | 1993 | 0.040 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2017 | 29 | 0.030 |
Why?
| | Histone Code | 1 | 2017 | 34 | 0.030 |
Why?
| | Rubella Vaccine | 1 | 1997 | 7 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 455 | 0.030 |
Why?
| | Program Evaluation | 1 | 2021 | 898 | 0.030 |
Why?
| | Apolipoprotein B-100 | 1 | 2016 | 10 | 0.030 |
Why?
| | Apolipoprotein E2 | 1 | 2016 | 3 | 0.030 |
Why?
| | Rubella | 1 | 1997 | 24 | 0.030 |
Why?
| | Neoplasms | 1 | 2012 | 2671 | 0.030 |
Why?
| | Adipocytes | 1 | 2018 | 222 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2020 | 648 | 0.030 |
Why?
| | Workflow | 1 | 2018 | 165 | 0.030 |
Why?
| | Preceptorship | 1 | 1997 | 66 | 0.030 |
Why?
| | GPI-Linked Proteins | 1 | 2017 | 73 | 0.030 |
Why?
| | Selection, Genetic | 1 | 2019 | 273 | 0.030 |
Why?
| | Time Factors | 2 | 2019 | 6828 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2019 | 229 | 0.030 |
Why?
| | Interleukin-33 | 1 | 2017 | 50 | 0.030 |
Why?
| | Denmark | 1 | 2016 | 46 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2018 | 499 | 0.030 |
Why?
| | Demography | 1 | 2017 | 291 | 0.030 |
Why?
| | Mean Platelet Volume | 1 | 2016 | 3 | 0.030 |
Why?
| | Data Accuracy | 1 | 2017 | 65 | 0.030 |
Why?
| | Allelic Imbalance | 1 | 2016 | 9 | 0.030 |
Why?
| | Erythrocyte Indices | 1 | 2016 | 30 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1710 | 0.030 |
Why?
| | Massachusetts | 1 | 2017 | 172 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2005 | 1996 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5131 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2016 | 55 | 0.030 |
Why?
| | China | 1 | 2017 | 217 | 0.030 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2016 | 90 | 0.030 |
Why?
| | Hematocrit | 1 | 2016 | 96 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 89 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2014 | 1091 | 0.030 |
Why?
| | Stearic Acids | 1 | 2015 | 15 | 0.030 |
Why?
| | DNA | 1 | 2023 | 1459 | 0.030 |
Why?
| | Sarcoglycans | 1 | 2015 | 5 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 307 | 0.030 |
Why?
| | Lung Volume Measurements | 1 | 2015 | 46 | 0.030 |
Why?
| | Computed Tomography Angiography | 1 | 2016 | 129 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1509 | 0.030 |
Why?
| | STAT1 Transcription Factor | 1 | 2015 | 72 | 0.030 |
Why?
| | Protein Transport | 1 | 2017 | 445 | 0.030 |
Why?
| | Bias | 1 | 2016 | 218 | 0.030 |
Why?
| | HTLV-I Infections | 1 | 1995 | 24 | 0.030 |
Why?
| | Glucose-6-Phosphatase | 1 | 2015 | 33 | 0.030 |
Why?
| | Vascular Calcification | 1 | 2016 | 108 | 0.030 |
Why?
| | Social Class | 1 | 2017 | 282 | 0.030 |
Why?
| | Nutritional Status | 1 | 2017 | 350 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 346 | 0.030 |
Why?
| | Pneumothorax | 1 | 2014 | 38 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2017 | 338 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2014 | 42 | 0.030 |
Why?
| | Coronary Angiography | 1 | 2016 | 317 | 0.030 |
Why?
| | Potassium Channels | 1 | 2015 | 151 | 0.030 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2015 | 82 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2019 | 860 | 0.030 |
Why?
| | Host-Parasite Interactions | 1 | 2015 | 114 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2057 | 0.030 |
Why?
| | Myosin Heavy Chains | 1 | 2015 | 192 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 552 | 0.030 |
Why?
| | Hemoglobins | 1 | 2016 | 353 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2018 | 442 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2022 | 1100 | 0.030 |
Why?
| | Diet, Western | 1 | 2014 | 81 | 0.030 |
Why?
| | Health Policy | 1 | 2017 | 388 | 0.030 |
Why?
| | alpha 1-Antitrypsin | 1 | 2014 | 108 | 0.030 |
Why?
| | Deferoxamine | 1 | 1993 | 24 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 843 | 0.030 |
Why?
| | Jamaica | 1 | 2013 | 5 | 0.030 |
Why?
| | Cotinine | 1 | 2013 | 77 | 0.030 |
Why?
| | District of Columbia | 1 | 2013 | 28 | 0.030 |
Why?
| | Societies, Dental | 1 | 1993 | 2 | 0.030 |
Why?
| | Metabolic Networks and Pathways | 1 | 2014 | 180 | 0.030 |
Why?
| | Aluminum | 1 | 1993 | 42 | 0.030 |
Why?
| | Gene Order | 1 | 2012 | 26 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2019 | 2486 | 0.030 |
Why?
| | New York | 1 | 2013 | 126 | 0.020 |
Why?
| | Educational Status | 1 | 2015 | 470 | 0.020 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2012 | 19 | 0.020 |
Why?
| | Dynactin Complex | 1 | 2012 | 4 | 0.020 |
Why?
| | Parathyroid Hormone | 1 | 1993 | 108 | 0.020 |
Why?
| | Immunity, Mucosal | 1 | 2013 | 97 | 0.020 |
Why?
| | Organizational Policy | 1 | 1993 | 84 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2009 | 5778 | 0.020 |
Why?
| | Untranslated Regions | 1 | 2012 | 3 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 889 | 0.020 |
Why?
| | Statistics, Nonparametric | 2 | 2005 | 431 | 0.020 |
Why?
| | Wales | 1 | 2011 | 23 | 0.020 |
Why?
| | Chemokine CXCL2 | 1 | 2011 | 43 | 0.020 |
Why?
| | Adolescent Development | 1 | 2012 | 86 | 0.020 |
Why?
| | England | 1 | 2011 | 97 | 0.020 |
Why?
| | X Chromosome Inactivation | 1 | 2011 | 25 | 0.020 |
Why?
| | Canada | 1 | 2012 | 418 | 0.020 |
Why?
| | Eicosapentaenoic Acid | 1 | 2011 | 39 | 0.020 |
Why?
| | Epidemiologic Methods | 1 | 2011 | 97 | 0.020 |
Why?
| | Luciferases | 1 | 2011 | 150 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2014 | 513 | 0.020 |
Why?
| | Microsatellite Repeats | 2 | 2003 | 168 | 0.020 |
Why?
| | Biological Evolution | 1 | 2015 | 474 | 0.020 |
Why?
| | Costa Rica | 1 | 2010 | 19 | 0.020 |
Why?
| | Overweight | 1 | 2015 | 558 | 0.020 |
Why?
| | Pulmonary Fibrosis | 1 | 2014 | 402 | 0.020 |
Why?
| | Iron | 1 | 1993 | 313 | 0.020 |
Why?
| | Artifacts | 1 | 2011 | 129 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1793 | 0.020 |
Why?
| | Salmeterol Xinafoate | 1 | 2010 | 41 | 0.020 |
Why?
| | Codon, Nonsense | 1 | 2010 | 44 | 0.020 |
Why?
| | Age Distribution | 1 | 2011 | 392 | 0.020 |
Why?
| | Sex Distribution | 1 | 2011 | 375 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2011 | 133 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2015 | 771 | 0.020 |
Why?
| | Bone and Bones | 1 | 1993 | 317 | 0.020 |
Why?
| | Introns | 1 | 2011 | 258 | 0.020 |
Why?
| | Markov Chains | 1 | 2010 | 126 | 0.020 |
Why?
| | Albuterol | 1 | 2010 | 110 | 0.020 |
Why?
| | Urban Population | 1 | 2012 | 479 | 0.020 |
Why?
| | Kainic Acid | 1 | 2009 | 35 | 0.020 |
Why?
| | Plasmids | 1 | 2010 | 363 | 0.020 |
Why?
| | Nicotine | 1 | 2012 | 334 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2010 | 239 | 0.020 |
Why?
| | Waist Circumference | 1 | 2010 | 143 | 0.020 |
Why?
| | Excitatory Amino Acid Agonists | 1 | 2009 | 39 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1316 | 0.020 |
Why?
| | Acute Disease | 1 | 2012 | 1007 | 0.020 |
Why?
| | DNA Replication | 1 | 2011 | 238 | 0.020 |
Why?
| | Biopsy | 1 | 1993 | 1129 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2009 | 164 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2009 | 3015 | 0.020 |
Why?
| | Bronchodilator Agents | 1 | 2010 | 252 | 0.020 |
Why?
| | Disease | 1 | 2009 | 98 | 0.020 |
Why?
| | Hospitals | 1 | 1993 | 691 | 0.020 |
Why?
| | Korea | 1 | 2007 | 16 | 0.020 |
Why?
| | Spirometry | 1 | 2009 | 281 | 0.020 |
Why?
| | Quality of Life | 1 | 2019 | 2892 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1946 | 0.020 |
Why?
| | beta-Thromboglobulin | 1 | 2007 | 3 | 0.020 |
Why?
| | Binding Sites | 1 | 2010 | 1303 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2010 | 483 | 0.020 |
Why?
| | Drug Resistance | 1 | 2007 | 169 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1719 | 0.020 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2006 | 33 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2009 | 578 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2005 | 115 | 0.020 |
Why?
| | Genetic Testing | 2 | 1999 | 460 | 0.020 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2005 | 44 | 0.020 |
Why?
| | Hepatitis A Antibodies | 1 | 2005 | 3 | 0.010 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2005 | 42 | 0.010 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2005 | 30 | 0.010 |
Why?
| | Hepatitis A | 1 | 2005 | 26 | 0.010 |
Why?
| | Receptors, Virus | 1 | 2005 | 83 | 0.010 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 2004 | 26 | 0.010 |
Why?
| | Seroepidemiologic Studies | 1 | 2005 | 165 | 0.010 |
Why?
| | Antigens, Dermatophagoides | 1 | 2004 | 10 | 0.010 |
Why?
| | U937 Cells | 1 | 2004 | 24 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2009 | 1738 | 0.010 |
Why?
| | Chromosomes, Human, Pair 20 | 1 | 2004 | 17 | 0.010 |
Why?
| | NIH 3T3 Cells | 1 | 2004 | 144 | 0.010 |
Why?
| | Gene Deletion | 1 | 2006 | 391 | 0.010 |
Why?
| | Receptor, Anaphylatoxin C5a | 1 | 2004 | 30 | 0.010 |
Why?
| | Germany | 1 | 2004 | 121 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2018 | 10811 | 0.010 |
Why?
| | 3' Untranslated Regions | 1 | 2004 | 145 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2007 | 347 | 0.010 |
Why?
| | Aquaporins | 1 | 2001 | 8 | 0.010 |
Why?
| | Chimera | 1 | 2001 | 58 | 0.010 |
Why?
| | Osmosis | 1 | 2001 | 17 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 2001 | 137 | 0.010 |
Why?
| | Optics and Photonics | 1 | 2001 | 43 | 0.010 |
Why?
| | Permeability | 1 | 2001 | 161 | 0.010 |
Why?
| | Western Australia | 1 | 2001 | 8 | 0.010 |
Why?
| | Lasers | 1 | 2001 | 130 | 0.010 |
Why?
| | HIV-2 | 1 | 2000 | 18 | 0.010 |
Why?
| | Cost Control | 1 | 2000 | 39 | 0.010 |
Why?
| | Herpesvirus 6, Human | 1 | 2000 | 14 | 0.010 |
Why?
| | Toxoplasma | 1 | 2000 | 42 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 2000 | 157 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 2000 | 166 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2004 | 2900 | 0.010 |
Why?
| | Expert Testimony | 1 | 1999 | 39 | 0.010 |
Why?
| | Immunoglobulin M | 1 | 2000 | 289 | 0.010 |
Why?
| | Observer Variation | 1 | 1999 | 343 | 0.010 |
Why?
| | Water | 1 | 2001 | 460 | 0.010 |
Why?
| | Lymphocytes | 1 | 2000 | 397 | 0.010 |
Why?
| | Rubella virus | 1 | 1997 | 7 | 0.010 |
Why?
| | Paresthesia | 1 | 1997 | 15 | 0.010 |
Why?
| | Arthralgia | 1 | 1997 | 56 | 0.010 |
Why?
| | Vaccines, Attenuated | 1 | 1997 | 132 | 0.010 |
Why?
| | Muscular Diseases | 1 | 1997 | 114 | 0.010 |
Why?
| | Arthritis | 1 | 1997 | 95 | 0.010 |
Why?
| | HIV-1 | 1 | 2000 | 864 | 0.010 |
Why?
| | Postpartum Period | 1 | 1997 | 340 | 0.010 |
Why?
| | Pain | 1 | 1997 | 756 | 0.010 |
Why?
| | Physicians | 1 | 1999 | 910 | 0.010 |
Why?
| | Vaccination | 1 | 1997 | 1381 | 0.000 |
Why?
|
|
Mathias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|